Here, we demonstrated that induction of colitis was associated with a significant increase in NOS2 and VEGF expression and the euphol treatment consistently blocked their up-regulation after DSS-induced colitis, suggesting that blocking intestinal inflammation and patho-angiogenesis through inhibiting NOS2 and VEGF expression during IBD progression may be, at least in part, the explanation of how euphol attenuates experimental colonic inflammation. This evidence concerns the gene VEGFA and inflammatory bowel disease.